Anna Orlova
Professor at Institutionen för läkemedelskemi; Theranostics
- Telephone:
- +46 18 471 42 39, +46 73 992 28 46, +46 18 471 53 03
- Mobile phone:
- +46 73 992 28 46
- E-mail:
- anna.orlova@ilk.uu.se
- Visiting address:
- Dag Hammarskjöldsv 14C, 3tr
- Postal address:
- Dag Hammarskjöldsv 14C, 3tr
751 83 Uppsala
Download contact information for Anna Orlova at Institutionen för läkemedelskemi; Theranostics
Senior Lecturer/Associate Professor at Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Vladimir Tolmachev
- Mobile phone:
- +46 73 992 28 46
- E-mail:
- anna.orlova@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
Molecular imaging may improve treatment of prostate cancer by better staging, personalising management and evaluation of therapy response. Our approach to visualization of prostate cancer is radionuclide targeting of the prostate tumour markers.
Publications
Recent publications
- Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology (2024)
- Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors (2024)
- The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial (2023)
- Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics (2023)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
All publications
Articles
- Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology (2024)
- Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors (2024)
- The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial (2023)
- Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics (2023)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
- Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) (2023)
- Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer (2023)
- Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors (2023)
- Synthesis, I-123-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures (2023)
- Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity (2023)
- Radionuclide Therapy of HER2-Expressing Xenografts Using [Lu-177]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab (2023)
- Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer (2023)
- Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3 (2023)
- Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc-99m and I-125 (2023)
- Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model (2023)
- Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs (2023)
- Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer (2022)
- Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts (2022)
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer (2022)
- Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis (2022)
- Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071 (2022)
- Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT (2022)
- Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands (2022)
- Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3 (2022)
- Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts (2022)
- Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules (2022)
- Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy (2022)
- Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 (2022)
- Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer (2021)
- Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules (2021)
- Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer (2021)
- Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 (2021)
- Affibody-Derived Drug Conjugates Targeting HER2 (2021)
- Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein (2021)
- Radionuclide therapy using ABD-fused ADAPT scaffold protein (2021)
- Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027 (2021)
- Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake (2021)
- The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR (2021)
- A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers (2021)
- Ga-66-PET-imaging of GRPR-expression in prostate cancer (2021)
- HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers (2021)
- PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology (2021)
- Comparative Evaluation of Novel Lu-177-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting (2021)
- The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer (2021)
- Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model (2021)
- Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model (2021)
- The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy (2021)
- Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer (2020)
- Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer (2020)
- Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 (2020)
- HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions (2020)
- Imaging using radiolabelled targeted proteins (2020)
- Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches (2020)
- Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. (2020)
- Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model (2020)
- Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer (2020)
- Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting (2020)
- Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules (2020)
- Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules (2020)
- Affibody Molecules as Targeting Vectors for PET Imaging (2020)
- Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1 (2020)
- Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1 (2020)
- Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer (2019)
- Molecular Design of HER3-Targeting Affibody Molecules (2019)
- Comparative Evaluation of Two DARPin Variants (2019)
- Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates (2019)
- Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts (2019)
- Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours (2019)
- Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A (2019)
- Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-Z(EGFR:2377) (2019)
- Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26 (2019)
- Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 (2019)
- Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer (2019)
- Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart (2019)
- Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules (2019)
- Optimization of HER3 expression imaging using affibody molecules (2019)
- Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake (2019)
- Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 (2019)
- Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3 (2019)
- Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 (2019)
- Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging (2019)
- Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting (2019)
- Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs (2018)
- Affibody-derived drug conjugates (2018)
- Selection of the most optimal ADAPT6-based probe for imaging of HER2 using PET and SPECT (2018)
- Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe (2018)
- Same-day imaging using small proteins (2018)
- Radionuclide tumor targeting using ADAPT scaffold proteins (2018)
- Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga (2018)
- Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate (2018)
- GRPR-targeted radiotherapy using the Lu-177-labeled GRPR-antagonist DOTAGA-PEG(2)-RM26 (2018)
- Selection of optimal macrocyclic chelator for high contrast PET imaging of gastrin releasing peptide receptor using cobalt-labeled bombesin antagonist RM26 (2018)
- Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab (2018)
- Imaging contrast of HER3 expression using monomeric affibody-based imaging probe can be improved by co-injection of affibody trimer (2018)
- Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules (2018)
- Comparative evaluation of anti-EFGR affibody molecules labelled with gallium-68 and zirconium-89 using desferrioxamine B as a chelator (2018)
- Preclinical Evaluation of [Ga-68]Ga-DFO-ZEGFR:2377 (2018)
- Optimization of molecular design of Ga-68-labeled affibody molecule for PET imaging of HER3 expression (2018)
- PP15 89Zr-Siderophore-Affibody conjugates for imaging EGFR expression (2018)
- Cyclic versus Noncyclic Chelating Scaffold for Zr-89-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression (2018)
- Molecular design of radiocopper-labelled Affibody molecules (2018)
- Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Molecular Imaging of HER2 Expression in Cancer Using SPECT (2018)
- Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors (2018)
- Development of a PET Imaging Approach for Selection of Patients for Affibody-Based PNA-Mediated Pretargeted Radionuclide Therapy (2018)
- Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy (2018)
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting (2018)
- In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin- binding therapeutic affibody construct (2017)
- The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule (2017)
- Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m (2017)
- Radiocobalt-labeled anti-HER1 affibody molecule DOTA-Z(EGFR:2377) for imaging of low HER1 expression in prostate cancer pre-clinical model (2017)
- Novel high affinity affibody for radionuclide imaging of VEGFR2 in glioma vasculature (2017)
- High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26 (2017)
- GRPR-Targeted Radiotherapy (2017)
- Influence of composition of cysteine-containing peptide based chelators on biodistribution of Tc-99m-labelled anti-EGFR affibody molecules (2017)
- Optimization of affibody molecule for imaging of HER3 expression (2017)
- Evaluation of radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression (2017)
- Optimal molecular design of radiocopper-labelled affibody molecules (2017)
- Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu-64 Using NOTA and NODAGA (2017)
- Improving of molecular design of a novel Affibody-fused HER2-recognising anticancer toxin using radionuclide-based techniques (2016)
- Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin (2016)
- Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2016)
- Comparative evaluation of Lu-177-HP2 and In-111-HP2, secondary agents for affibody-based PNA-mediated radionuclide pretargeting (2016)
- Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR (2016)
- PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR (2016)
- Evaluation of Affibody Molecules for Radionuclide Imaging of Carbonic Abhydrase IX Expression In Vivo (2016)
- Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX (2016)
- Influence of the N-terminal amino acid sequence on imaging properties of In-111-labeled anti-HER2 scaffold protein ADAPT6 (2016)
- Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6 (2016)
- Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors (2016)
- Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. (2016)
- Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct Z(VEGFR2)-Bp(2) (2016)
- Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. (2016)
- In vivo evaluation of pharmacokinetics, tumors targeting and therapeutic efficacy of a novel format of HER3-targeting affibody molecule with prolonged blood circulation (2016)
- Imaging of EGFR Expression Using 99mTC-Labelled ZEGFR:2377 Affibody Molecule (2016)
- Development and Evaluation of Radiocobalt-labelled Affibody Molecule for Next Day PET Imaging of HER3 Expression (2016)
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients (2016)
- Synthesis of 11C-labelled Sulfonyl Carbamates via a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols and [11C]CO (2016)
- Synthesis of C-11-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [C-11]CO (2016)
- Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT (2016)
- Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules (2016)
- Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2015)
- Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients (2015)
- Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors (2015)
- The use of radiocobalt as a label improves PET imaging of EGFR using DOTA-conjugated affibody molecules (2015)
- ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers (2015)
- Feasibility of Affibody molecule-based PNA-mediated pretargeting (2015)
- Influence of Histidine-Containing Tags on Biodistribution of Radiolabelled ADAPT-Based Imaging Probes (2015)
- Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression (2015)
- Development of radiocobalt-labeled GRPR antagonist NOTA-PEG2-RM26. (2015)
- Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or x-ray radiation with three different LigandTracer® devices (2015)
- Influence of chelators on targeting properties of In-111 and Ga-68 labeled GRPR antagonist (2015)
- Affibody-mediated PET imaging of HER3 expression in malignant tumours (2015)
- Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity (2015)
- The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 (2015)
- Comparing the measured affinity of (111) In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer (R) devices (2015)
- Good manufacturing practice compliant production of a Ga-68-labelled Affibody agent for breast cancer imaging (2015)
- Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re (2014)
- Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine (2014)
- 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors (2014)
- In Vitro Therapy Modeling of HER2 Targeting Therapy in Disseminated Prostate Cancer (2014)
- 111In-labeled NOTA-conjugated Affibody molecules for visualization of HER3 expression in malignant tumors (2014)
- Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging (2014)
- Position for Site-Specific Attachment of a DOTA Chelator to Synthetic Affibody Molecules Has a Different Influence on the Targeting Properties of 68Ga- Compared to 111In-Labeled Conjugates. (2014)
- Evaluation of 99mTc-ZIGF1R:4551-GGGC Affibody Molecule, a New Construct for Imaging the Insulin-like Growth Factor Type 1 Receptor Expression (2014)
- Influence of chelators on biodistribution and targeting properties of GRPR antagonist (2014)
- Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3 08699 affibody molecule (2014)
- PET Imaging of HER3-Expression in Tumours Using a 68Ga-Labeled Affibody Molecule (2014)
- Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with (18)F-4-Fluorobenzaldehyde (2014)
- Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer (2014)
- Gallium-68-labeled affibody molecule for PET imaging of PDGFR beta expression in vivo (2014)
- Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo (2014)
- Development of a I-124-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer (2014)
- Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591 (2014)
- Histidine-Rich Glycoprotein Uptake and Turnover Is Mediated by Mononuclear Phagocytes. (2014)
- The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a Ga-68-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin (2014)
- GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination (2014)
- Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re (2013)
- Influence of Nuclides and Chelators on Imaging Using Affibody Molecules (2013)
- In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors (2013)
- HAHAHA, HEHEHE, HIHIHI, or HKHKHK (2013)
- Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging (2013)
- Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification (2013)
- Increase of HER2 expression in prostate cancer cell lines as reaction on external irradiation (2013)
- [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours (2013)
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein (2013)
- Feasibility of radionuclide imaging of HER3-expressing tumours using technetium-99m labeled affibody molecules (2013)
- Feasibility of radionuclide imaging of HER3-expressing tumors using affibody molecules (2013)
- Influence of macrocyclic chelators on biodistribution and targeting properties of 68Ga-labeled synthetic Affibody molecules. Comparison with 111In-labeled counterparts (2013)
- Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules (2013)
- HAHAHA-, HIHIHI-. HKHKHK. HHHHHH- and HEHEHE- tags (2013)
- In vivo imaging of PDGFR beta expression using In-111-DOTA-Z09591 Affibody molecule (2013)
- Imaging of PDGFRbeta expression in vivo using Affibody molecule In-111-DOTA-Z09591 (2013)
- Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging (2013)
- GRPR antagonist NOTA-P2-RM26 labeled with fluorine-18 (2013)
- In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging (2013)
- Detecting ligand interactions with G protein-coupled receptors in real-time on living cells (2013)
- (AlF)-F-18-labelling of NOTA-P2-RM26 and its evaluation as a PET ligand for GRPR/BB2 (2013)
- Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA (2012)
- Comparative evaluation of anti-HER2 affibody molecules labeled with 68Ga and 111In using maleimido derivatives of DOTA and NODAGA (2012)
- Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of (99m)Tc-labeled recombinant Affibody molecules (2012)
- Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line (2012)
- Influence of DOTA chelator position on biodistribution and targeting properties of 111 In-labelled anti-HER2 affibody molecules (2012)
- Liver uptake of radiolabeled targeting proteins and peptides (2012)
- Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus (2012)
- Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. (2012)
- Development of 124I-labelled anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer (2012)
- Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of In-111-Labeled Synthetic Anti-HER2 Affibody Molecules (2012)
- Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging (2012)
- Site-specific radioiodination of HER2-targeting affibody molecules using iodophenetylmaleimide decreases renal uptake of radioactivity (2012)
- 99mTc(CO)3-HEHEHE-ZIGF1R:4551 affibody molecule, a poteintial imaging agent for visualization of insulin-like growth factor-1 receptor in malignant tumors (2012)
- Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551 (2012)
- Tumor Targeting Using Affibody Molecules (2012)
- Synthesis and characterization of a high affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging (2012)
- Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with Tc-99m, In-111 and I-125 (2011)
- Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts (2011)
- Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer (2011)
- Imaging agents for in vivo molecular profiling of disseminated prostate cancer (2011)
- Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules (2011)
- Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate (2011)
- Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels (2011)
- Engineering of C-terminal cysteine-containing peptide-based chelators improves biodistribution of HER2-targeting 99mTc-labeled Affibody molecules (2011)
- Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties (2011)
- Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold (2010)
- Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules (2010)
- Quantification of internalization of EGFR-binding Affibody molecules (2010)
- Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. (2010)
- Influence of an aliphatic linker between DOTA and synthetic Affibody molecule on targeting properties (2010)
- Re-186-maSGS-Z(HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours (2010)
- HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [Tc-99m(CO)(3)](+), and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation (2010)
- HEHEHE (2010)
- Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets (2010)
- Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR In-111-DOTA-Z(EGFR:2377) Affibody molecule (2010)
- Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response (2010)
- A HER2-binding Affibody molecule labelled with 68Ga for PET imaging (2010)
- HER2 targeting with Tc-99m-labeled second generation synthetic Affibody molecule (2010)
- Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors (2010)
- Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine (2009)
- Positioning of Tc-99m-chelators influences radiolabeling, stability and biodistribution of Affibody molecules (2009)
- Synthesis and chemoselective intramolecular cross-linking of a HER2-binding Affibody (2009)
- On the selection of a tracer for PET imaging of HER2-expressing tumors (2009)
- Update on Affibody molecules for in vivo imaging of targets for cancer therapy (2009)
- Affibody molecules for epidermal growth factor receptor targeting in vivo (2009)
- Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding (2009)
- The influence of Bz-DOTA and CHX-AaEuro(3)-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules (2009)
- Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging (2009)
- Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules (2008)
- Targeting EGFR and HER2 with 211At-labeled molecules (2008)
- Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake (2008)
- Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule (2008)
- In vivo and in vitro uptake of In-111, delivered with the affibody molecule(Z(EGFR:955))(2), in EGFR expressing tumour cells (2008)
- Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules (2008)
- Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules (2008)
- Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2 (2008)
- Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence (2007)
- 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule (2007)
- Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma (2007)
- Update (2007)
- Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors (2007)
- Synthetic affibody molecules (2007)
- Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors (2007)
- In Vivo Evaluation of Cysteine-Based Chelators for Attachment of 99mTc to Tumor-Targeting Affibody Molecules (2007)
- Affibody molecules (2007)
- Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule (2007)
- (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors (2007)
- Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand (2007)
- Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated (2006)
- Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI) (2006)
- Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI) (2006)
- Tumor imaging using a picomolar affinity HER2 binding affibody molecule (2006)
- Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors (2006)
- Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice (2006)
- 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors (2006)
- In vitro characterization of 211 At-labeled antibody A33 (2005)
- [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo (2005)
- An Aminoacridine Derivative for Radionuclide Therapy: Dna-Binding Properties Studied in a Novel Cell-Free in vitro Assay (2005)
- An aminoacridine derivative for radionuclide therapy (2005)
- Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti-HER2 Affibody (2005)
- Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET (2005)
- Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker (2004)
- Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives (2004)
- Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB1 H11 (2004)
- Targeting against epidermal growth factor receptors (2004)
- Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media (2004)
- [177Lu]Bz-DTPA-EGF (2004)
- Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice (2004)
- Feasibility of isotopic exchange in system [125I] iodide – undecahydro-iodo-closo-dodecaborate (2-) anion (2003)
- Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF (2003)
- [111In]Bz-DTPA-hEGF (2003)
- Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides (2003)
- [111In]-DTPA-hEGF and [111In]-Bz-DTPA-hEGF (2002)
- Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33 (2002)
- [111In] benzyl-DTPA-EGF, a new potential radiopeptide for targeting of glioma (2002)
- Cellular processing of iodinated and astatinated trastuzumab in cultured SK-BR-3 breast cancer cells (2002)
- The use of benzyl isothiocyanate derivative of closo-dodecaborate dianion for indirect radioiodination and radiobromination of monoclonal antibodies (2002)
- Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma loclizing agent (2002)
- Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells (2001)
- Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET (2000)
- Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I (2000)
- Synthesis of [211At] N-[8-(acridin-9-ylamino)-octyl]-3- astatobenzamide, an astatinated DNA intercalator (2000)
- Cellular processing of (125)I- and (111)in-labeled epidermal growth factor(EGF) bound to cultured A431 tumor cells (2000)
- Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells (2000)
- Closo-dodecaborate(2-)anion as a potential prosthetic group for attachment of astatine to proteins (2000)
- Optimization of iodination of [125I]-N-succinimidyl-para-iodobenzoate using Chloromine-T for labeling of proteins (2000)
- Intercalators labelled with Auger emitting nuclides (1999)
- Closo-dodecaborate(2-) as a linker for iodination of macromolecules (1999)
- Labelling and in vivo evaluation of closo-dodecaborate as a linker for attachment of iodine to radiopharma-ceuticals (1997)
- Labelling of boron containing compounds with halogen isotopes (1997)
- Pharmacokinetics in tumour-bearing rats of directly and indirectly 76Br-brominated MAb A33
- Polyhedral boron clasters as linkers for attachment of radiohalogens to tumor targeting proteins. II. Radioiodination of monoclonal antibody using potassium [125I]-4-(isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (Iodo-DABI)
Chapters
- Methods for radiolabelling of monoclonal antibodies (2014)
- Radiohalogenated Polyhedral Borate Anaions for use in Targeted Oncological Radionuclide Therapy, Some Recent Developments (2003)
- Effect of ionising radiation on the labelling of closo-dodecaborate (2-) anion (2000)
- Closo-dodecaborate (2-) anion as a prosthetic group for labelling proteins with a astatine (2000)